Needham analyst Gil Blum has maintained their bullish stance on ARTV stock, giving a Buy rating yesterday.
Gil Blum has given his Buy rating due to a combination of factors including Artiva Biotherapeutics, Inc.’s promising pipeline and financial stability. The company is expected to release initial clinical data for its AlloNK therapy in autoimmune disorders in the first half of 2025, which is anticipated to be a significant near-term catalyst. Additionally, Artiva is actively enrolling participants in its Phase I study for SLE/LN and conducting an investigator-sponsored trial in various autoimmune disorders, with initial results expected in the same timeframe.
Artiva’s financial position is strong, ending the year 2024 with approximately $185 million, which is projected to support operations through the end of 2026. This financial stability, combined with the potential for positive clinical outcomes, underpins the Buy rating. The company’s strategy to differentiate itself through multiple early readouts in cell therapy for autoimmune disorders further supports the positive outlook.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
ARTV’s price has also changed dramatically for the past six months – from $15.110 to $3.990, which is a -73.59% drop .